Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Despite advances in pharmacotherapy, cardiovascular (CV) risk factors such as hypertension, diabetes mellitus, and obesity show persistent or increasing prevalence.
• These CV risk factors are frequently undertreated globally, even with established consensus guidelines.
• The early onset of obesity and diabetes in pediatric populations necessitates early interventions.

Purpose of the Study:

• To evaluate the role of lifestyle and pharmacologic interventions in modifying CV risk factors and improving glucose tolerance.
• To assess the comparative efficacy of different antihypertensive agents, particularly those blocking the renin-angiotensin system, in preventing diabetes.

Main Methods:

• Review of current clinical practices and guidelines for managing cardiovascular risk factors.
• Analysis of pharmacologic interventions, focusing on drugs that block the renin-angiotensin system.
• Comparative assessment of antihypertensive agents regarding their impact on diabetes incidence.

Main Results:

• Hypertension, diabetes mellitus, and obesity remain significant public health challenges with largely unchanged or increasing prevalence.
• Drugs blocking the renin-angiotensin system demonstrate a reduced incidence of diabetes compared to other antihypertensive medications.
• Early implementation of interventions is crucial due to the increasing incidence of these conditions from childhood.

Conclusions:

• Renin-angiotensin system blockers should be considered primary therapy for hypertensive patients at high risk for diabetes and CV disease.
• Integrated lifestyle and pharmacologic strategies are essential for managing CV risk factors and improving metabolic health.
• Addressing the global undertreatment of CV risk factors requires adherence to guidelines and consideration of specific drug classes.